Introduction: At least 9 therapeutic options are now available for unresectable WDpNET patients. Whether all lines can be administrated before tumor or toxic-related deaths is currently unknown.
Aim(s): The primary endpoint was to determine OS as a function of the number of therapeutic lines. Secondary endpoints were to determine cumulative toxicity as defined by the frequency of modified serious adverse events (mSAE) as a function of the number of lines.
Materials and methods: Patients with unresectable WDpNET treated between 1998 and 2010 at the Gustave Roussy were studied. Locoregional (TACE) and systemic lines including somatostatin analogs or interferon[48 patients], targeted therapies (sunitinib, everolimus), PRRT, chemotherapies (dacarbazine-, streptozotocin-, oxaliplatin-based) were counted. Cumulative toxicity was defined by mSAE, including permanent toxicity (persistent grade 2-5).
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Others
Presenting Author: Amandine Berdelou
, Malka D
, Leboulleux S
, Boige V
, Chougnet C
, Burtin P
, Debaere T
, Caramella C
, Elias D
, Schlumberger M
, Ducreux M
, Baudin E
To read results and conclusion, please login ...
Further abstracts you may be interested in